AstraZeneca PLC
NASDAQ:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
NASDAQ:AZN
Watchlist
Price: 65.35 USD 1.41% Market Closed
Market Cap: 202.6B USD
Have any thoughts about
AstraZeneca PLC?
Write Note
Section:
 

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is 105.75 USD. Compared to the current market price of 65.35 USD, AstraZeneca PLC is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
Base Case
105.75 USD
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.1
P/S
P/S
Price to Sales
4.1
vs History
95
vs Industry
25
Median 3Y
4.6
Median 5Y
4.7
Industry
2.5
Forward
0
More Details
31
P/E
P/E
Price to Earnings
31
vs History
87
vs Industry
11
Median 3Y
37.2
Median 5Y
38.5
Industry
21.8
Forward
0.2
More Details
18.1
P/OCF
P/OCF
Price to OCF
18.1
vs History
98
vs Industry
17
Median 3Y
21.8
Median 5Y
24
Industry
16.1
More Details
22
P/FCFE
P/FCFE
Price to FCFE
22
vs History
66
vs Industry
15
Median 3Y
38.9
Median 5Y
29.7
Industry
23.8
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
87
vs Industry
11
Median 3Y
5.4
Median 5Y
5.9
Industry
2.1
More Details
53.2
EV/S
EV/S
Enterprise Value to Sales
53.2
vs History
41
vs Industry
5
Median 3Y
53.4
Median 5Y
49.1
Industry
2.7
Forward
0.5
More Details
64.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
64.7
vs History
41
vs Industry
4
Median 3Y
65
Median 5Y
61
Industry
5.2
More Details
169.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
169.2
vs History
33
vs Industry
2
Median 3Y
166.2
Median 5Y
161.2
Industry
13.5
Forward
1.4
More Details
253.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
253.5
vs History
77
vs Industry
1
Median 3Y
257.7
Median 5Y
275.6
Industry
16.8
Forward
1.6
More Details
236.3
EV/OCF
EV/OCF
Enterprise Value to OCF
236.3
vs History
69
vs Industry
1
Median 3Y
240.5
Median 5Y
244.9
Industry
15.2
More Details
375.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
375.3
vs History
65
vs Industry
1
Median 3Y
381.5
Median 5Y
410.5
Industry
19.3
More Details
34
EV/IC
EV/IC
Enterprise Value to IC
34
vs History
11
vs Industry
4
Median 3Y
30.8
Median 5Y
29.9
Industry
1.9
More Details

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
NASDAQ:AZN
159B USD 4.1 31 169.2 253.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average P/S: 382 947.6
4.1
35%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average P/E: 31.6
31
177%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average EV/EBITDA: 436.9
169.2
64%
2.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average EV/EBIT: 1 869
253.5
131%
1.9
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.